Continued expansion of the POLB 002 patent family following European Patent Office approval
By Elric Langton | 14 April 2022
I have a financial interest in Poolbeg Pharma
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, strengthening its intellectual property (Iβ¦